Abbott has agreed to pay approximately $670 million to resolve lawsuits involving about 2,000 claims related to its preterm infant formulas, following a $495 million jury verdict in the Gill case. The company denies any liability and maintains that its formulas are safe and essential for premature infants, supported by medical authorities and regulatory agencies. Despite ongoing litigation involving thousands more claims, Abbott views this settlement as a constructive step toward resolving disputes while emphasizing the critical role of preterm formulas in neonatal care. Abbott continues to challenge questionable claims and highlights the consensus among health experts that these formulas do not cause necrotizing enterocolitis (NEC).
Abbott Laboratories showed strong performance in Q2 2026 with a 4.8% year-over-year sales increase and a 100 basis point rise in adjusted gross margin to 58.0%. Growth was fueled by its acquisition of Exact Sciences for cancer diagnostics, innovative...
Abbott Laboratories reported a strong Q2 performance, beating earnings expectations and raising its full-year guidance. The company's acquisition of Exact Sciences is expected to boost long-term growth, supporting a projected 10.4% compound annual gr...
The National Association of Community Health Centers (NACHC) and Abbott have launched a multi-year "Food for Health" initiative to make nutrition a core part of primary care at over 1,500 Community Health Centers across the U.S. This program includes...
MiniMed has launched its MiniMed Flex system in the U.S., featuring the Instinct sensor made by Abbott. This system is notable for being MiniMed's smallest insulin pump that can be controlled via an app, paired with the world's smallest sensor that l...
